Aurinia Pharmaceuticals Inc.
AUPH
$8.18
$0.080.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 32.76% | 24.32% | 37.83% | 46.19% | 58.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.76% | 24.32% | 37.83% | 46.19% | 58.59% |
| Cost of Revenue | -12.57% | -55.42% | -8.61% | -2.03% | 39.09% |
| Gross Profit | 56.79% | 71.90% | 62.03% | 77.63% | 71.32% |
| SG&A Expenses | -26.04% | -11.29% | -4.56% | -4.85% | 5.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -56.08% | 72.93% | 92.01% | -1,522.41% | 246.27% |
| Total Operating Expenses | -24.37% | -20.85% | -0.05% | -11.13% | 21.82% |
| Operating Income | 132.73% | 172.24% | 97.27% | 77.79% | 15.40% |
| Income Before Tax | 104.44% | 212.61% | 112.18% | 61.16% | -4.86% |
| Income Tax Expenses | -155.77% | 53.36% | 217.76% | 69.50% | -46.32% |
| Earnings from Continuing Operations | 105.32% | 206.72% | 106.28% | 58.98% | -3.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 105.32% | 206.72% | 106.28% | 58.98% | -3.18% |
| EBIT | 132.73% | 172.24% | 97.27% | 77.79% | 15.40% |
| EBITDA | 167.17% | 251.27% | 128.49% | 94.03% | 32.48% |
| EPS Basic | 105.37% | 206.59% | 106.21% | 59.39% | -2.45% |
| Normalized Basic EPS | 162.86% | 212.52% | 120.90% | 87.25% | -4.15% |
| EPS Diluted | 105.37% | 206.27% | 106.21% | 59.39% | -2.45% |
| Normalized Diluted EPS | 160.52% | 210.43% | 120.90% | 87.25% | -4.15% |
| Average Basic Shares Outstanding | -0.52% | 0.14% | 0.39% | 0.96% | 0.72% |
| Average Diluted Shares Outstanding | 3.32% | 1.96% | 0.93% | 0.96% | 0.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |